Accessed on 31.01.2020
Suivant les recommandations de la Stratégie Stop TB le Sénégal s’inscrit dans une optique de renforcement de la prise en charge de la tuberculose dans ce groupe vulnérable. Pour ce faire, la mise en place de documents standardisés et consensuels de référence, adap...tés au contexte sénégalais est indispensable. Ce guide s’adresse à tous les prestataires de soins impliqués dans la prise en charge des enfants. Il peut être utilisé aussi bien au niveau opérationnel qu’au niveau des hôpitaux.
more
La publicación describe los procedimientos estandarizados para la atención integral de las personas diagnosticadas con tuberculosis y Virus de Inmunodeficiencia Humana en los servicios de salud a nivel nacional, así como los procesos de atención integral en las personas diagnosticadas con tuberc...ulosis y virus de Inmunodeficiencia Humana (VIH), que incluyen acciones de prevención, diagnóstico, tratamiento y seguimiento.
more
ASLM in collaboration with the Africa Centres for Disease Control and Prevention, and in partnership with the Clinton Health Access Initiative, Amref and Last Mile Health present the Quality Assurance Framework for SARS-CoV-2 Antigen Rapid Testing for Diagnosis of COVID-19. This framework aims to pr...ovide general technical guidance to African Union Members States on the rollout, establishment, implementation, monitoring, and evaluation of SARS-CoV-2 Ag RDT interventions so as to effectively and efficiently detect, control and minimise errors in the performance of COVID-19 laboratory testing processes. It describes the core components for quality assurance, resources mobilisation and advocacy for scale up, monitoring, evaluation, learning and accountability for SARS-CoV-2 implementation.
more
De acuerdo al informe de ONUSIDA sobre la Epidemia Mundial de sida 2008, se
estima que en el año 2007, 370.000 niños menores de 15 años se infectaron con el
VIH. A nivel mundial, el número de niños menores de 15 años que viven con el VIH
aumentó de 1,6 millones en 2001 a 2 millones en 2...007.
Los efectos de la epidemia entre los niños pequeños son graves y de largo alcance. El sida amenaza con causar un retroceso en los años de progreso constante y en la supervivencia de los niños; ha duplicado la mortalidad infantil en los países más afectados por esta epidemia.
more
Resumen para Equipos de Salud Edición 2021-2022
Las presentes recomendaciones se encuentran dirigidas a los miembros del equipo de salud que asisten niñas, niños y adolescentes (NNyA) que viven con VIH. También se dirigen a los responsables jurisdiccionales que participan en el proceso de gesti...ón de acceso a tratamientos antiretrovirales recomendados. El objetivo es brindar directrices para optimizar el cuidado y tratamiento antiretroviral de NNyA, con opciones más seguras y eficaces, basadas en la mejor evidencia disponible.
more
Mise en oeuvre de l’alerte précoce et réponse notamment la surveillance fondée sur les évènements
The article "Barriers and determinants of asthma control in children and adolescents in Africa: a systematic review" analyzes factors contributing to poor asthma control in African youth. Based on studies conducted between 2014 and 2019 in Nigeria, Uganda, and South Africa, the review identifies key... challenges such as limited access to asthma diagnosis, inadequate use of inhaled corticosteroids, and environmental and socio-economic factors. It finds that urban living, older age, and concurrent allergic conditions significantly affect asthma management. The study emphasizes the need for improved diagnostic tools, better access to treatment, and tailored public health interventions to enhance asthma outcomes in African children.
more
The document is a comprehensive practical guide for managing cholera epidemics. It includes detailed instructions on outbreak investigation, control measures, case management, and the organization of treatment facilities. It emphasizes strategies such as rehydration therapy, water sanitation, hygien...e promotion, and vaccination to prevent the spread of cholera. The guide serves as a resource for healthcare professionals, logisticians, and public health officials to respond effectively to cholera outbreaks.
more
Available in Englisch, French, Spanish and Chinese
The document provides guidelines for the management of acute diarrhoea, highlighting improved oral rehydration solutions (ORS) with reduced osmolarity and zinc supplementation. It emphasizes their effectiveness in reducing the duration and severity... of diarrhoeal episodes and preventing future cases. Aimed at families, communities, and healthcare professionals, it seeks to integrate these practices into routine care at home and in health centers.
more
The COTS Cholera Outbreak Training and Shigellosis Program Pocket Card provides essential guidelines for health promotion workers to prevent and manage cholera and shigellosis outbreaks. It emphasizes proper sanitation, hygiene practices, safe water handling, and food safety as the primary methods f...or disease control. Key recommendations include handwashing, disinfecting water with chlorine, using latrines, and ensuring safe food preparation. The document also outlines hospital policies, waste disposal procedures, and safety measures for healthcare workers dealing with diarrheal diseases. Additionally, it provides dehydration assessment guidelines, treatment protocols using Oral Rehydration Solution (ORS) and IV fluids, and appropriate antibiotic treatments for both cholera and shigellosis. The goal is to equip healthcare workers with quick-reference tools to effectively contain outbreaks and prevent further transmission.
more
La respuesta a los brotes de cólera suele centrarse en los aspectos médicos que son importantes para que disminuya la mortalidad. Sin embargo, para limitar la propagación de la enfermedad se necesita una respuesta más integral. Dado que la respuesta a los brotes a menudo la dirigen profesionales... médicos, pueden quedar desatendidos otros aspectos tales como las cuestiones medioambientales o de comunicación.
more
The Guidance on global monitoring for diabetes prevention and control by WHO provides a comprehensive framework to support countries in tracking and managing diabetes prevention, care, and outcomes. This document outlines indicators across 4 domains: health system determinants, service delivery, ris...k factors, and outcomes/impacts. The guidance helps countries align their monitoring efforts with WHO’s global diabetes targets, Global Diabetes Compact, and relevant global NCD targets.
more
Health care waste can be difficult to treat and dispose of safely. The environmental and health impacts of waste put extra pressure on resources. Therefore, it is important to try and reduce the quantities of waste wherever possible. Ensure waste is segregated properly at the point of disposal. It i...s cheaper and easier to manage general waste through a municipal waste system than infectious or sharps waste which needs treatment before final disposal. Organic general wastes like food and paper can be composted rather than being wasted. Non- hazardous general waste may also be sorted for recycling.
more
WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines.
Updated risk rates for hospital admission in patients with non-severe COVID-19
The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19.
The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients.
This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines:
**High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%.
**Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%.
Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk.
Review of COVID-19 treatments for people with non-severe COVID-19
WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022.
If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead.
WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission.
For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol.
WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials.
The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials.
more